Key Points {#d30e405}
==========

Coronavirus disease 2019 (COVID-19) has a significant impact on the cardiovascular (CV) system, both directly and indirectly.COVID-19 infection utilizes the angiotensin-converting enzyme 2 receptor for entry into the cellInfection can cause several CV syndromes, including myocardial damage, acute coronary syndrome, and arrhythmia.COVID-19 can result in hypercoagulability, resulting in venous thromboembolism and pulmonary embolism, with consequent right ventricular dysfunction or failure.Clinicians should also be aware of the CV effects of drugs used for COVID-19 treatment.

Introduction {#Sec1}
============

Coronavirus disease 2019 (COVID-19) is a rapidly spreading novel infectious disease of the human respiratory system caused by a newly discovered enveloped RNA β-coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) \[[@CR1]\]. Coronavirus has been responsible for previous epidemics, such as SARS-CoV and the Middle East Respiratory Syndrome (MERS)-CoV (Table [1](#Tab1){ref-type="table"}). Since diagnosis of the index case, linked to the seafood and wet animal wholesale market in Wuhan, Hubei Province, China, in December 2019 \[[@CR2]\], the disease has spread to involve more than 200 countries. As of 29 May 2020, the total number of cases in the US was 1,719,827, including 101,711 deaths \[[@CR3]\]. The first case of COVID-19 was reported in the US on 30 January 2020, and, since then, more than 1.5 million cases have been diagnosed. Given the substantial morbidity and mortality caused by this disease within a short timeframe and the high rate of human-to-human transmission, the World Health Organization (WHO) declared COVID-19 a pandemic on 11 March 2020 \[[@CR4]\].Table 1Timeline of coronavirus infection affecting humans1965: Tyrrell and Bynoe1 identified a virus named B8142002--2003: Severe acute respiratory syndrome (SARS)2012: Middle East Respiratory Syndrome2019--2020: Covid-19 (the illness caused by SARS-CoV-2 infection)First reported case to the WHO Country Office in China on 31 December 2019On 20 January 2020, the CDC confirmed a positive test for 2019-nCoV, by rRT-PCR, in an individual in the USIn a meeting on 30 January 2020, per the International Health Regulations (2005), the WHO declared the outbreak was a Public Health Emergency of International ConcernOn 11 February 2020, the WHO Director-General announced that the disease caused by this new CoV was 'COVID-19'WHO raised the threat to the CoV epidemic to the 'very high' level on 28 February 2020On 11 March 2020 WHO declared COVID-19 a pandemic*CDC* Centers for Disease Control and Prevention, *CoV* coronavirus, *rRT-PCR* real-time reverse-transcriptase--polymerase-chain-reaction, *WHO* World Health Organization

It is noteworthy that COVID-19 has a lower fatality rate than the previous outbreak of SARS, but has a more remarkable capacity to spread quickly, thus making it an ideal infection to result in a pandemic. Our understanding of this disease is still evolving; however, a substantial amount of data has emerged recently indicating not just pulmonary involvement but significant involvement, both direct and indirect, of the cardiovascular (CV) system \[[@CR5]--[@CR7]\]. Interestingly, cardiac complications are not only prevalent but also signify a poor prognosis and may develop late in the course of more severe cases of the disease. In this review, we briefly discuss the pathogenesis, clinical manifestations, and diagnosis of COVID-19, with an emphasis on cardiac involvement, management strategies, and potential future implications, understanding that this is an area where information is accruing and changing rapidly.

Pathogenesis {#Sec2}
============

The lung is the principal organ affected in the early stages of COVID-19. The virus utilizes the angiotensin-converting enzyme 2 (ACE2) receptor, abundant in the lower respiratory tract, for entry into the cells. Importantly, ACE2 is also expressed in the heart, intestinal epithelium, vascular endothelium, and the kidneys, making all of these organs potential targets \[[@CR4]\]. The *S*-glycoprotein receptor located on the surface of the virus consists of two subunits, S1 and S2, which attach to the ACE2 receptor \[[@CR5], [@CR6]\]. S1 determines the virus host range and cellular tropism, whereas S2 mediates fusion of the virus-cell membrane followed by the release of viral RNA into the cytoplasm. This is followed by the translation of new viral particles, with subsequent release to infect other cells \[[@CR7], [@CR8]\].

After the initial infection, the acute disease progression can be divided into three distinct phases (early infection phase, pulmonary phase, and a hyperinflammation phase) with significant overlap \[[@CR9]--[@CR11]\]. The hyperinflammation stage is characterized by a cytokine storm, leading to immune-mediated injuries to distant organs \[[@CR11]\]. Studies have demonstrated significant elevation of inflammatory markers, including interleukin (IL)-6, IL-2, IL-7, tumor necrosis factor (TNF)-α, interferon-inducible protein (IP)-10, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, granulocyte colony stimulating factor (G-CSF), C-reactive protein (CRP), procalcitonin, and ferritin \[[@CR12]--[@CR17]\].

The exact pathogenesis of cardiac involvement is not entirely clear. Increased cardiac biomarkers, including troponin T, have been shown to be linearly correlated with inflammatory markers, indicating that myocardial injury is likely related to underlying inflammation \[[@CR18]\]. Several mechanisms of cardiac damage are likely at play, including direct myocardial damage by the virus itself, hypoxic injury mediated by respiratory failure, indirect injury mediated by cytokines secondary to systemic inflammatory response, myocardial infarction (MI) due to plaque rupture secondary to systemic inflammation, the prothrombotic state produced by severe systemic inflammation, and ischemia from myocardial supply--demand mismatch (Fig. [1](#Fig1){ref-type="fig"}). ACE2 receptor-mediated direct cardiac injury also remains a possibility. ACE2 receptors are expressed in cardiac pericytes and endothelial cells, and animal data suggest that their direct dysfunction secondary to viral infection or secondary inflammation may precipitate MI \[[@CR19], [@CR20]\].Fig. 1Schematic representation of the COVID-19 structure and route of infection. This figure describes the structure of the SARS-CoV-2. In the respiratory system, the virus spike protein binds with the ACE2 receptor in respiratory epithelial cells and internalizes and forms a membrane fusion complex, which causes the release of the viral RNA into the host cell and results in respiratory infection. Through different pathways, the virus induces the proinflammatory response by induction of T- and B-cells and synthesis of type I IFNs, which limit the spread of the virus and cause a cytokine storm, while induction of the macrophage causes ingestion of the viral antigen \[this image is generated with the help of Biorender\]. *SARS-CoV-2* severe acute respiratory syndrome coronavirus 2, *ACE2* angiotensin converting enzyme 2, *IFNs* interferons, *NK* natural killer, *TH17* T-helper 17, *IL* interleukin, *TNF* tumor necrosis factor, *MCP* monocyte chemoattractant protein

Clinical Manifestations {#Sec3}
=======================

The median incubation period of COVID-19 has been determined to be 5.7 days, with 97.5% of patients developing symptoms within 12.5 days of exposure \[[@CR21]\]. The most common symptoms are non-specific, including fever (88%), fatigue (70%), dry cough (67.7%), anorexia (40%), and myalgia (35%). Anosmia and dysgeusia have also been reported as notable and somewhat specific symptoms. Upper respiratory tract symptoms such as rhinorrhea are conspicuously less common. Gastrointestinal symptoms, including nausea and diarrhea \[[@CR22], [@CR23]\] are also less common.

The initial experience from China suggests that approximately 81% of infected patients experience mild disease, with severe disease developing in 14%. Pneumonia with acute respiratory distress syndrome (ARDS) is the most common severe manifestation. Critical illness with septic shock and multi-organ dysfunction has been reported in 5% of patients \[[@CR13]\].

Cardiac Manifestations {#Sec4}
----------------------

As previously discussed, cardiac injury is a common problem associated with COVID-19 \[[@CR24]\]. Acute coronary syndrome (ACS), arrhythmias, and blood pressure fluctuations have been reported to occur, in addition to cardiac dysfunction. The incidence of arrhythmia has not been clearly reported, although it is expected to be more frequently seen in critically ill patients; these include tachyarrhythmia, bradyarrhythmia, and asystole \[[@CR16], [@CR25]\]. In a study conducted in Wuhan, cardiac conditions, including heart failure (HF), contributed to 40% of the mortality, either acting alone or in conjunction with respiratory failure \[[@CR15]\].

Cardiovascular Effects {#Sec5}
======================

Previous viral epidemics have been associated with a significant increase in the incidence of myocarditis, cardiomyopathy, HF, MI, arrhythmias, and sudden cardiac death \[[@CR26]--[@CR28]\]. It was therefore not unexpected to see a higher incidence of CV events in those infected with COVID-19. On the other hand, the presence of pre-existing cardiac conditions appears to increase the chance of complications, including death, in COVID-19 patients. As reported in a meta-analysis of patients admitted with COVID-19, the incidence of CV disease (CVD) was 16.4% in non-intensive care unit (ICU) patients, and three times higher in those requiring the ICU \[[@CR29]\]. In the following sections, we highlight various baseline CV comorbidities and disorders that have been reported to date with COVID-19 (Table [2](#Tab2){ref-type="table"}).Table 2Summarizing published case studies showing baseline cardiovascular comorbidities in COVID-affected patientsAuthorPlace of studyDate accepted/publishedTotal no. of patientsMean age, years% of male patients% of female patients% of HTN% of DM% of CVD/CAD% of other cardiac diseases^a^Chen et al. \[[@CR30]\]ChinaJanuary 20209955.16832NA1240NAHuang et al. \[[@CR13]\]ChinaJanuary 202041497327152015NAZhang et al. \[[@CR31]\]ChinaFebruary 20201405750.749.33012.153.6Wang et al. \[[@CR32]\]ChinaMarch 202033969495140.81615.7NAWu et al. \[[@CR33]\]ChinaMarch 202028043.153.9346.07NA12.14^d^20.4NAZhou et al. \[[@CR17]\]ChinaMarch 202019156623830198NAChen et al. \[[@CR34]\]ChinaMarch 20202746262.437.634178NALiang et al. \[[@CR35]\]ChinaMarch 2020159048.957.342.716.98.23.7NAMcMichael et al. \[[@CR36]\]USAMarch 20201018331.768.367.331.760.4NACao et al. \[[@CR37]\]ChinaApril 202010254524827.510.84.914.7^b^; 17.6^c^Shao et al. \[[@CR38]\]ChinaApril 20201366966.233.830.22011NARichardson et al. \[[@CR39]\]USAApril 202057006360.339.756.633.811.16.9Goyal et al. \[[@CR40]\]USAApril 202039362.260.639.450.125.213.77.4Grasselli et al. \[[@CR41]\]ItalyApril 20201591638218491721NA*CAD* coronary artery disease, *CVD* cardiovascular disease, *DM* diabetes mellitus, *HTN* hypertension, *NA* not available^a^Other cardiac diseases include congestive heart failure, acute cardiac injury, arrhythmia^b^Acute cardiac injury^c^Arrhythmia^d^Endocrine system disease

Myocardial Damage {#Sec6}
-----------------

Cardiotropic viruses directly attack cardiac cells at the initial phase, followed by a secondary inflammatory response that can lead to further cardiac damage. It is likely that coronavirus is following a similar pathway. Indeed, the ACE2 receptor plays a role in the direct cardiac damage, as well as vascular involvement in COVID-19 infection. In autopsies from the SARS outbreak in 2002, 35% of heart samples revealed the presence of viral RNA in the myocardium, and it was associated with reduced ACE2 expression. It is believed SARS-CoV-2 may share the same mechanism, with direct cardiac muscle damage playing a role in both the myocarditis and HF in COVID-19-infected individuals. Cardiac muscle involvement has been evident by increased cardiac biomarkers in a sizable portion of patients \[[@CR42]\]. Additionally, autopsy studies of COVID-19 have demonstrated the presence of mononuclear infiltrate in the myocardium, with related cardiomyocyte necrosis \[[@CR43]\]. Finally, acute lung injury and ARDS result in right heart strain, with right ventricular (RV) dilation and dysfunction, and high positive end expiratory pressure (PEEP) use while on ventilation can also worsen cardiac function \[[@CR44]\].

Many studies have shown poorer outcomes, including mortality, in patients with elevated biomarkers (such as cardiac troponin, creatinine kinase, pro-brain natriuretic peptide \[BNP\]) in COVID-19-related ARDS \[[@CR45], [@CR46]\]. In a prospective cohort study of 179 patients with COVID-19 pneumonia, a cardiac troponin I level of ≥ 0.05 ng/mL was found to be strongly associated with increased mortality (hazard ratio \[HR\] 4.077, 95% confidence interval \[CI\] 1.166‒14.253; *p* \< 0.001) \[[@CR47]\]. In another study of 273 patients, cardiac biomarkers (N-terminal \[NT\] pro-BNP, cardiac troponin, and myoglobin) were significantly higher in severe and critical cases compared with mild cases \[[@CR48]\]. Another study aimed at correlating the change in troponin levels with the progression of COVID-19 disease, and showed that 37.5% of patients with normal troponin at admission had a rise in troponin during hospitalization, which peaked in the week before demise \[[@CR49]\]. A meta-analysis of 341 patients in China confirmed the findings of these studies, reinforcing the importance of troponin measurement at admission and/or during hospitalization to determine the severity of the disease.

Importantly, troponin can be elevated in COVID patients with underlying renal impairment \[[@CR42]\]. In this setting, elevations of other cardiac biomarkers will be more reliable as an indicator of underlying cardiac injury. Zhou et al. and Li et al. have described increased levels of creatine kinase--myocardial band (CK-MB), myoglobin, and NT-pro-BNP in COVID patients, which also correlated with the severity of disease \[[@CR50], [@CR51]\].

EKG and echocardiographic findings, in conjunction with biomarker elevation, help diagnose and predict prognosis in COVID-19 patients with cardiac involvement. Notably, data on the correlation between biomarkers, clinical manifestations and echocardiographic findings are lacking, and further study of this relationship may ultimately help in early risk stratification \[[@CR52]\]. Although case reports of myocarditis in COVID-19 patients exist, it is unclear whether the myocarditis is induced by the virus directly or results from an inflammatory response \[[@CR53]\]. A case of myopericarditis complicated by cardiac tamponade was also reported in the literature \[[@CR54]\]. Isolated hemorrhagic pericardial effusion with tamponade without the features of myocarditis has also been demonstrated \[[@CR55]\]. Recently, two cases have been reported with apparent Takotsubo syndrome in the setting of COVID infection \[[@CR56], [@CR57]\].

Although cardiac involvement usually occurs later in the course of COVID-19, acute HF secondary to myocardial involvement or previously existing cardiac disease could be the presenting symptoms in COVID-19 infection in almost one-quarter of patients. The management of myocardial dysfunction in COVID-19 leading to HF is similar to other forms of HF. Optimization of fluid balance, monitoring of electrolytes and renal function, and early use of the cardiac catheterization laboratory and invasive monitoring all play important roles in managing COVID patients with HF \[[@CR58]\].

Coronary Ischemia/Infarction {#Sec7}
----------------------------

Coronary involvement and ischemia have been seen, including ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI), with several mechanisms explaining coronary artery involvement. As ACE2 is expressed in vascular endothelial cells, direct viral infection can lead to plaque instability and type 1 MI. Plaque instability and rupture may also result from the severe systemic inflammatory response in the third phase of the disease. COVID-19 can additionally precipitate type II MI by demand ischemia as patients get sicker. Hypoxia secondary to lung involvement, and fever and tachycardia secondary to sepsis, further worsen the cardiac function. Coronary artery involvement can further be produced by a microangiopathy that has also been described. Such small vessel involvement can be due to systemic vasculitis or to microembolization from ACS or disseminated hypercoagulability impairing blood flow \[[@CR42]\].

The management of STEMI has been particularly difficult. Currently, multiple factors have been sources of delay for a primary percutaneous coronary intervention (PCI) approach, including determining whether STEMI or COVID is the primary problem, and deciphering mimickers of STEMI, such as Takotsubo cardiomyopathy, myocarditis, RV failure, or massive pulmonary embolism (PE). In the emergency department, screening for COVID infection may take some time, and, within the catheterization laboratory, additional time is needed for donning and doffing personal protective equipment (PPE). In addition, redeployment of staff has resulted in shortages to team availability. From a procedure room standpoint, catheterization laboratories are positive pressure rooms with a significantly higher risk of aerosolization, and therefore some have been converted to negative pressure rooms, while others must be fitted with high efficiency particulate air (HEPA) filters. In addition, specific protocols for anesthesia, emergent intubation, and protection of staff and equipment have been implemented, all of which add time to the care of these patients.

A small study evaluating primary PCI in seven patients presenting with STEMI calculated the time from onset of symptoms to medical contact to be a median of 318 min, compared with a median of 82.5--91.5 min recorded in the previous year. Similarly, the door-to-device time was almost 30 min longer, at a median of 110 min, compared with a median of 84.9 min in the previous year \[[@CR59]\]. When put in the context of existing data on door-to-balloon (D2B) time and CV outcomes, while 60--90 min estimates the absolute risk reduction of 1-year mortality at 2.4%, the odds worsen when this time increases to 90--120 min. In the same study, an incremental increase in the D2B time by 1 h was associated with a 64% increase in 1-year mortality (HR 1.90, 95% CI 1.51--2.39; *p* \< 0.001) \[[@CR60]\].

According to recent statements by the American College of Cardiology (ACC) Interventional Council and Society for Cardiovascular Angiography and Intervention (SCAI) regarding the management of STEMI during the COVID-19 pandemic, primary PCI should remain the standard in these patients, with fibrinolytic therapy reserved for patients with relative contraindications or those with severe bilateral COVID pneumonia (PNR) or ARDS, given the poor overall prognosis (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR61]\]. NSTEMI patients with suspected or confirmed COVID-19 should be managed by aggressive medical management until the test comes back, and then risk stratification. High-risk patients or hemodynamically unstable patients should be managed by early invasive strategy (\< 24 h), as in all patients with NSTEMI. A non-invasive or medical approach would be best for low-risk patients.Fig. 2Management of STEMI in COVID-19 confirmed/suspected patients. *ACEi* angiotensin-converting enzyme inhibitor, *BP* blood pressure, *CPR* cardiopulmonary resuscitation, *DBP* diastolic blood pressure, *GI* gastrointestinal, *GU* genitourinary, *H/O* history of, *HR* heart rate, *ICH* intracranial hemorrhage, *LA* left arm, *PCI* percutaneous coronary intervention, *RA* right arm, *SBP* systolic blood pressure, *STEMI* ST-elevation myocardial infarction. \*High risk individuals: 1. HR \> 100/min and SBP \< 100 mm of Hg, 2. pulmonary edema, 3. signs of shock, 4. CPR required. \*\*Medical therapy: 1. antiplatelet, 2. anticoagulation, 3. high intensity statin, 4. beta blocker/ACEi

Coronary computed tomography (CT) angiography may be considered for risk stratification \[[@CR61]\], and has the added advantage of evaluating the lung parenchyma for signs of COVID pneumonia or other etiologies of decompensation, such as PE with RV failure. This strategy has been adopted at some institutions for patients in whom there are both pulmonary and cardiac manifestations, especially in the setting of fever.

Arrhythmias {#Sec8}
-----------

The incidence of arrhythmia is currently unknown in COVID-19 patients, with preliminary data suggesting an incidence of 16.7% among hospitalized patients and 44.4% of ICU admissions \[[@CR16]\]. Both ventricular and atrial arrhythmias have been seen, in addition to sinus tachycardia due to clinical decompensation, fever, or sepsis. The cause of arrhythmia could be myocarditis, hypoxia, or electrolyte derangement seen in these patients, and in many cases may be reactive. Management of these arrhythmias are largely supportive, with control of the underlying clinical condition, electrolyte repletion, and pharmacologic antiarrhythmic therapy.

Specific mention should be made regarding drugs to treat COVID-19 and the potential for pro-arrhythmia. Although data on outcomes with hydroxychloroquine are not available, it is widely used in hospitals for critical patients. The drug is a known inhibitor of the potassium channel Kv11.1 present in the heart, potentially increasing the QTc interval and predisposing the patient to fatal ventricular tachyarrhythmias (torsades de point). In the setting of a very long half-life of 40 days, this adverse effect is rarely seen in clinical practice in patients routinely treated for malaria and rheumatological conditions such as systemic lupus erythematosus \[[@CR62], [@CR63]\], but the incidence alongside COVID-19, especially in severe cases, remains unclear. According to the recommendations from the Heart Rhythm Society released recently in collaboration with the ACC and AHA, hydroxychloroquine use must be closely monitored in certain patient groups. These include individuals with a known history of long QT syndrome, those with deranged renal function, those with electrolyte abnormalities such as hypokalemia and hypomagnesemia, and those prescribed other QTc-prolonging drugs \[[@CR64]\]. When administered in combination with azithromycin, which is also known to prolong the QTc interval, dose adjustments may be necessary \[[@CR65]\]. Recently, the US FDA has mentioned the risk of this combination therapy \[[@CR66]\].

Arrhythmias leading to cardiac arrest deserve special mention. Cardiopulmonary resuscitation (CPR) with chest compressions is very high risk for aerosolization of virus, and a minimum number of caregivers should be inside the room, with full PPE. To minimize prolonged exposure, mechanical CPR devices may be considered, and all attempts should be made to prioritize immediate intubation into a closed circuit by anesthesiologists so that the duration of any aerosolization is kept to a minimum. While waiting for intubation, bag/mask ventilation with filter is recommended. The choice of tools for intubation should be determined by the expected success rate, with preference given to devices with the highest first-pass rate. Video laryngoscopy should be used where possible to ensure quick and effective airway management, and minimal to no disconnections in the closed-circuit should be the goal \[[@CR67]\].

Venous Thromboembolism {#Sec9}
----------------------

An increased risk of blood clot formation resulting from hypercoagulability has been previously noted with SARS and MERS \[[@CR68]\]. Similarly, COVID-19 has been associated with a hypercoagulable state. Dysfunction of endothelial cells induced by infection results in excess thrombin generation and fibrinolysis shutdown. The hypoxia found in severe COVID-19 can also stimulate thrombosis through increasing blood viscosity. A hypoxia-inducible transcription factor-dependent signaling pathway also plays a role in increasing the coagulability of the blood \[[@CR69]\]. A study by Panigada et al. showed an increased risk of venous thrombosis in COVID-19-affected individuals \[[@CR70]\]. One study involving 184 patients showed CT angiography and/or ultrasonography confirmed venous thromboembolism (VTE) in 27% of patients and arterial thrombotic events in 3.7% of patients. PE was the most frequent thrombotic complication and may be massive with significant RV failure \[[@CR71]\]. The diagnosis of VTE and PE in COVID patients is challenging. The International Society on Thrombosis and Hemostasis (ISTH) advocates the use of laboratory tests, including [d]{.smallcaps}-dimers, prothrombin time, and platelet count, to stratify patients at risk of increased blood clot formation \[[@CR72]\]; however, elevated [d]{.smallcaps}-dimer levels are not specific to the diagnosis of VTE. If only a high [d]{.smallcaps}-dimer level is relied on for diagnosis, it will unnecessarily increase the utilization of CT angiography for infected patients, without much benefit. In addition, it may worsen kidney function due to contrast use in the setting of poor cardiac output and hypoxia from COVID-19 \[[@CR73]\]. Maintaining isolation while doing the tests is also another hurdle for hospitals. Echocardiogram may aid in the diagnosis of large PE by finding isolated RV dilation or failure, or a saddle PE, although it may be difficult to visualize \[[@CR74]\].

Prophylaxis with low-molecular-weight heparin (LMWH) is recommended for every patient, if not contraindicated \[[@CR72]\]. In a study involving 449 patients with severe COVID-19, anticoagulant therapy, mainly with LMWH, was associated with lower mortality in patients with markedly elevated D-dimer \[[@CR75]\]. The use of unfractionated heparin may be superior in critically ill patients with underlying renal failure, which is a contraindication to LMWH. Interestingly, in vivo models of coronavirus infection have shown that administration of unfractionated heparin functions as a decoy receptor, reducing viral infectivity and potentially augmenting viral clearance \[[@CR76]\]. Heparin also has anti-inflammatory effects, reduces myocardial inflammation, and has shown antiviral effects in animal models \[[@CR77]\]. Tissue plasminogen activator (TPA) has shown transient improvement in a case series but there is still a lack of data regarding the safety of use in this setting. Furthermore, there have been no data on the adequate dose of TPA \[[@CR78]\].

Direct-acting oral anticoagulants (DOACs) can also be considered in the treatment of thromboembolism in COVID-19 infection. However, drug interactions between DOAC and antiviral treatments, as well as dosing concerns in the setting of changing kidney function, need to be considered before prescribing these drugs \[[@CR79]\]. Asakura et al. have proposed the use of nafamostat, a synthetic serine protease inhibitor, as a short-acting anticoagulant with antiviral properties, along with heparin, in COVID patients; more data are required regarding the efficacy of this agent \[[@CR80]\]. A study has shown an increased incidence of VTE even in anticoagulated patients, but the small sample size and retrospective nature are two limitations of that study \[[@CR81]\]. Recently published clinical data have suggested that systemic anticoagulation may be associated with positive outcomes among patients hospitalized with COVID-19, but that study has some limitations, including its observational nature and unobserved confounding factors \[[@CR82]\].

Antihypertensive Medications {#Sec10}
============================

It is estimated that 15--30% of COVID-19 patients have hypertension (HTN) \[[@CR16]\]. Indeed, a meta-analysis (*n* = 46,248) including eight studies from China demonstrated that the most common cardiac comorbidity was HTN (17 ± 7%, 95% CI 14--22%) \[[@CR83]\]. ACE2 receptor expression is similar in adipose and non-adipose tissues, but as obese individuals have more adipose tissue in the body, they may have an increased number of receptors. Although some have reported obesity to be a risk factor for COVID infection, more data are required to see if obese individuals are indeed more vulnerable \[[@CR84]\].

Given the prevalent use of ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs), and the predominant role of ACE2 receptors in the disease pathogenesis, there has been some concern surrounding the use of these medications in COVID-19 patients. Animal data have supported that chronic use of ARBs elevates ACE2 receptor expression, and elevated ACE2 expression has potential protective CV effects \[[@CR85]\]. Zhang et al. recently published a retrospective, multicenter study including 1128 adult patients with COVID-19 and found a lower risk of all-cause mortality with inpatient use of ACEIs/ARBs compared with ACEIs/ARBs non-users \[[@CR86]\]. Jarcho et al. have highlighted three more recently published studies, showing no evidence of increased risk of infection or inpatient mortality in COVID-affected patients who continued on these medications \[[@CR87]\]. Another recent study has shown similar confirmation \[[@CR88]\]. Based on available data, most of the major society guidelines have recommended against stopping ACEIs/ARBs in patients already taking these medications, or initiating these medications in newly diagnosed patients \[[@CR89]--[@CR91]\].

Experimental COVID Drug Use and Cardiovascular Adverse effects {#Sec11}
==============================================================

A host of therapeutic agents have been employed to treat patients with COVID-19, however a detailed review of these is beyond the scope of this review. We focus on the most promising drugs that have been repurposed and used to treat this disease, emphasizing the CV adverse effects of these therapies and the known strategies to counter them. Among the treatments employed, chloroquine and hydroxychloroquine, antiretrovirals (lopinavir and ritonavir), ribavarin, remdesivir, corticosteroids, anticytokine agents (IL-6 inhibitors), and immunoglobulin therapy (convalescent plasma) have been prominent \[[@CR92]\]. Chloroquine and hydroxychloroquine have been used to treat patients with COVID-19 in small randomized clinical trials and are postulated to work by blocking viral entry into cells through endosomal trafficking and by exerting an immunomodulatory effect through cytokine attenuation. Both agents can cause QTc prolongation, as previously discussed, which can be aggravated by concomitant use of azithromycin, a macrolide antibiotic, and other fluoroquinolones. Baseline electrocardiography is recommended in patients to evaluate for prolonged QTc in specific high-risk populations, as previously discussed. Serial electrocardiography in critically ill patients following the initiation of these medications is useful to monitor \[[@CR65]\]. A detailed treatment workflow with hydroxychloroquine is provided in Fig. [3](#Fig3){ref-type="fig"}. Lopinavir and ritonavir also have the potential to cause QTc prolongation \[[@CR93]\]. Ribavirin has the potential to cause hemolytic anemia in high doses \[[@CR94]\], which can also increase CVD risk and hemodynamic instability. Table [3](#Tab3){ref-type="table"} summarizes the possible CV adverse effects of experimental therapies.Fig. 3Workflow for hydroxychloroquine therapy in COVID-19 patientsTable 3Treatment modalities used in CoVID-19 and CV adverse effectsTherapyRationale in CoVID-19 patientsCardiovascular adverse effectsChloroquine and hydroxychloroquine1. Inhibits the viral entry through endosomal trafficking2. Immunomodulatory effect through cytokine attenuationQTc prolongation, bundle branch block, AV block, ventricular arrhythmias, Torsades de pointeLopinavir/ritonavirLopinavir inhibits viral proteaseRitonavir inhibits CYP3A metabolism, increasing the half-life of lopinavirConduction abnormalitiesRemdesivirViral RNA polymerase inhibitorNo serious cardiac adverse effectsRibavirinInhibits viral RNA and DNA replicationHemolytic anemiaCorticosteroidsAnti-inflammatoryElectrolyte imbalance and hypertensionAnticytokine agents (tocilizumab)Inhibits IL-6 and cytokine stormRare hypertensionImmunoglobulin therapyAntibodies against the virus in the convalescent plasmaTransfusion-related acute lung injury leading to cardiopulmonary failureLow-molecular-weight heparinAnticoagulationBleeding in the cerebrovascular space, heparin-induced thrombocytopenia, deep vein thrombosis, and pulmonary embolismExtracorporeal membrane oxygenationAssisted extracorporeal circulation and physiologic gas exchange in cardiopulmonary failureDistal ischemia and thrombosisMechanical ventilationAssist spontaneous breathing in CoVID-19-induced ARDSDecreased cardiac output, respiratory alkalosis, increased intracranial pressure*ARDS* acute respiratory distress syndrome, *AV* atrioventricular, *CYP* cytochrome P450, *IL* interleukin

Future Complications and Implications {#Sec12}
=====================================

Apart from complications during the active phase of infection, as described herein, long-term sequelae of the disease remain a possibility despite complete viral clearance. Previous epidemics from similar viruses can be informative in providing some clues for the long-term CV complications of COVID-19. For example, the 2002 SARS epidemic caused metabolic alterations through an increase in the level of phosphatidylinositol and lysophosphatidylinositol in recovered SARS patients in comparison with healthy volunteers \[[@CR95]\]. This metabolic change was subsequently associated with hyperlipidemia and also with impaired glucose metabolism. Multiple studies have reported avascular necrosis as a long-term complication from the corticosteroids prescribed to SARS patients \[[@CR96], [@CR97]\]. However, the mechanism leading to these metabolic changes as a result of the viral infection remains unknown. Osteonecrosis is independently associated with an increased risk of adverse CV outcomes in SARS patients treated with corticosteroids and warrants further exploration \[[@CR98], [@CR99]\]. Psychiatric morbidities, including chronic fatigue syndrome, were also reported in patients who recovered from SARS \[[@CR100]\]. Given the strong association between psychiatric conditions, such as depression and chronic fatigue syndrome, and CVD, such as chronic HF and cardiac arrhythmias, the evidence backing long-term CV sequelae of these infections appears compelling \[[@CR101]--[@CR104]\].

The outbreak of the pandemic has led to the preservation of medical resources, in terms of hospital beds, medical personnel, and PPE, that have prioritized the care of COVID-19 patients. This has led to stratification and deferral of elective procedures, including structural and electrophysiology procedures \[[@CR105]\]. A recent study reported the decrease in cardiac catheterization/percutaneous intervention due to this shift in management protocol \[[@CR106]\], resulting in pharmacological management as the alternative. Telemedicine and teleconsultations are being implemented widely. As a result, there has been an unanticipated increase in urgent cases that occur while patients wait for their procedures. In addition, due to a fear of going to the hospital and contracting COVID, it appears many patients may have ignored important symptoms while at home, resulting in a large number of deaths indirectly related to the pandemic. This is particularly true for the incidence of STEMI, which showed a sharp decline during the pandemic, paralleling a similar sharp rise in patient deaths at home \[[@CR107]\]. Clearly, such an anticipated consequence of our response to pandemics must be mitigated in the future.

A surge of elective procedures is expected after this pandemic, and potentially an increased number of decompensated patients secondary to non-compliance, delayed elective procedures, and completed or late-presenting MI. A recent analysis showed a 38% decrease in primary PCI in the US during the COVID-19 pandemic, which is partly attributable to avoiding going to the hospital early for fear of contracting the infection in the hospital, misdiagnosis of STEMI, and more use of fibrinolysis \[[@CR106]\]. This would likely lead to an increase in the number of post-MI complications, such as mechanical complications, cardiogenic shock, cardiac rupture, post-MI angina, and reinfarction, that were not common previously because of prompt management by an invasive strategy. Some of these complications may not have presented due to deaths at home. Similarly, a significant decrease in ACS-related hospitalization rates across northern Italy has been noted \[[@CR108]\]. Interestingly, the incidence of out-of-hospital cardiac arrest has increased \[[@CR109]\]. Masking of symptoms such as shortness of breath, chest tightness, underlying poor clinical status of patients secondary to COVID, and fear of accessing the health care system may be the cause of such increased incidence.

Conclusion {#Sec13}
==========

As this new pandemic continues to unfurl, a variety of cardiac manifestations have become evident. There is a need for further research to better understand the spectrum of CV manifestations. Until a vaccine or potentially curative treatment is available, clinicians should be aware of the known cardiac involvement and address this at the outset to attenuate damage. In addition, we must be vigilant about the potential adverse effects and interactions of existing therapies.
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